東陽光藥(01558.HK)2019年純利同比增103.57%至19.18億元
格隆匯3月28日丨東陽光藥(01558.HK)公告,截至2019年12月31日止年度,營業額為人民幣62.2億元,較去年增長147.92%。税息、折舊及攤銷前溢利為人民幣25.59億元,較去年增長119.75%。公司權益股東應占溢利及全面收益總額(考慮可轉換債券影響)為人民幣19.18億元,較去年增長103.57%。每股基及攤薄盈利分別為人民幣4.27元和人民幣4.10元。
董事會建議派發截至2019年12月31日止年度通過未分配利潤向公司股東發行每1股現有股份送紅股1股(含税)及末期股息每股人民幣0.3元(含税)。紅股將通過未分配利潤轉換的方式發行。
公司核心產品磷酸奧司他韋是目前國內治療流行性感冒的一線用藥,可用於治療及預防甲型及乙型流感,並列入《流行性感冒診療方案(2019年版)》。隨着快速診斷成為流感確診病例的診斷依據一,以及提供病原學快速診斷服務的醫療機構數大幅度增加,流感報告病例數較往年明顯增加,公司產品的臨牀應用也將進一步拓寬。
報告期內,集團延續了四大銷售團隊的全面市場營銷戰略,分別是負責核心品種在排名二級及以上等級醫院的學術推廣的自營銷售隊伍、負責所有品種在以全科醫生為主的醫療機構(排名一級的醫院和診所)的自營銷售隊伍、負責所有品種在OTC藥店的自營銷售隊伍和負責普藥品種在排名二級及以上等級醫院的招商銷售隊伍。報告期內,公司亦開始拓展線上藥房渠道,並與多家知名線上渠道運營商展開合作。
截止2019年12月31日,集團銷售團隊共計4316人。四大銷售隊伍的建設將為集團產品羣在各個銷售渠道的全面放量奠定堅實的基礎。
集團堅守為每個人的健康的信條,堅持為病人提供高質量的藥物。圍繞這一信念,集團不斷完善生產製度建設,加強生產過程監管,持續不斷的改進產品和服務的質量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.